|
1
|
Allum WH, Blazeby JM, Griffin SM,
Cunningham D, Jankowski JA and Wong R: Association of Upper
Gastrointestinal Surgeons of Great Britain and Ireland, the British
Society of Gastroenterology and the British Association of Surgical
Oncology: Guidelines for the management of oesophageal and gastric
cancer. Gut. 60:1449–1472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bernini M and Bencini L: Multimodal
treatment of gastric cancer: Surgery, chemotherapy, radiotherapy
and timing. Int J Surg Oncol. 2012:2462902012.PubMed/NCBI
|
|
3
|
Yu C, Yu R, Zhu W, Song Y and Li T:
Intensity-modulated radiotherapy combined with chemotherapy for the
treatment of gastric cancer patients after standard D1/D2 surgery.
J Cancer Res Clin Oncol. 138:255–259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roukos DH: Current advances and changes in
treatment strategy may improve survival and quality of life in
patients with potentially curable gastric cancer. Ann Surg Oncol.
6:46–56. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu CD: Clinical study of nimotuzumab
combined with chemotherapy in the treatment of late stage gastric
cancer. Asian Pac J Cancer Prev. 15:10273–10276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao SR, Li LM, Xia HP, Wang GM, Xu HY and
Wang AR: Clinical observation on recombinant human endostatin
combined with chemotherapy for advanced gastrointestinal cancer.
Asian Pac J Cancer Prev. 16:4037–4040. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Zhong L, Liu BZ, Gao YJ, Gao YM
and Hu XX: Effect of GINS2 on proliferation and apoptosis in
leukemic cell line. Int J Med Sci. 10:1795–1804. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu YJ, Li YM, Hou XD, Guo C, Cao N and
Jiao ZY: Effect of tissue factor on invasion inhibition and
apoptosis inducing effect of oxaliplatin in human gastric cancer
cell. Asian Pac J Cancer Prev. 13:1845–1849. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan B, Liu L, Zhao Y, Xiu LJ, Sun DZ, Liu
X, Lu Y, Shi J, Zhang YC, Li YJ, et al: Xiaotan Sanjie decoction
attenuates tumor angiogenesis by manipulating Notch-1-regulated
proliferation of gastric cancer stem-like cells. World J
Gastroenterol. 20:13105–13118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu Y, Liu Y, Qian Y, Dai X, Yang L, Chen
J, Guo S and Hisamitsu T: Research on the efficacy of Celastrus
orbiculatus in suppressing TGF-β1-induced epithelial-mesenchymal
transition by inhibiting HSP27 and TNF-α-induced NF-κ B/ Snail
signaling pathway in human gastric adenocarcinoma. BMC Complement
Altern Med. 14:4332014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hung MH, Tai WT, Shiau CW and Chen KF:
Downregulation of signal transducer and activator of transcription
3 by sorafenib: A novel mechanism for hepatocellular carcinoma
therapy. World J Gastroenterol. 20:15269–15274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu H, Ren G, Wang T, Chen Y, Gong C, Bai
Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1
by IL-6/STAT3 transactivation promotes colorectal cancer
aggressiveness through epithelial-mesenchymal transition.
Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao X, Liu H, Zhang X, Zhang L, Li X, Wang
C and Sun S: Cell surface GRP78 accelerated breast cancer cell
proliferation and migration by activating STAT3. PLoS One.
10:e01256342015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peyser ND, Freilino M, Wang L, Zeng Y, Li
H, Johnson DE and Grandis JR: Frequent promoter hypermethylation of
PTPRT increases STAT3 activation and sensitivity to STAT3
inhibition in head and neck cancer. Oncogene. 2015.PubMed/NCBI
|
|
15
|
Wen W, Wu J, Liu L, Tian Y, Buettner R,
Hsieh MY, Horne D, Dellinger TH, Han ES, Jove R and Yim JH:
Synergistic anti-tumor effect of combined inhibition of EGFR and
JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 14:1002015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hossain DM, Pal SK, Moreira D, Duttagupta
P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S and Kortylewski M:
TLR9-targeted STAT3 silencing abrogates immunosuppressive activity
of myeloid-derived suppressor cells from prostate cancer patients.
Clin Cancer Res. 21:3771–3782. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon J, Ko YS, Cho SJ, Park J, Choi YS,
Choi Y, Pyo JS, Ye SK, Youn HD, Lee JS, et al: Signal transducers
and activators of transcription 3-induced metastatic potential in
gastric cancer cells is enhanced by glycogen synthase kinase-3β.
APMIS. 123:373–382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang YX, Cai H, Jiang G, Zhou TB and Wu H:
Silibinin inhibits proliferation, induces apoptosis and causes cell
cycle arrest in human gastric cancer MGC803 cells via STAT3 pathway
inhibition. Asian Pac J Cancer Prev. 15:6791–6798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Silva IT, Carvalho A, Lang KL, Dudek SE,
Masemann D, Durán FJ, Caro MS, Rapp UR, Wixler V, Schenkel EP, et
al: In vitro and in vivo antitumor activity of a novel
semisynthetic derivative of cucurbitacin B. PLoS One.
10:e01177942015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li ZJ, Shin JM, Choi DK, Lim SK, Yoon TJ,
Lee YH, Sohn KC, Im M, Lee Y, Seo YJ, et al: Inhibitory effect of
cucurbitacin B on imiquimod-induced skin inflammation. Biochem
Biophys Res Commun. 459:673–678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Bian ZG, Zhang Y, Wang JH, Kan L,
Wang X, Niu HY and He P: Cucurbitacin B inhibits proliferation and
induces apoptosis via STAT3 pathway inhibition in A549 lung cancer
cells. Mol Med Rep. 10:2905–2911. 2014.PubMed/NCBI
|
|
22
|
Iwanski GB, Lee DH, En-Gal S, Doan NB,
Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH and
Koeffler HP: Cucurbitacin B, a novel in vivo potentiator of
gemcitabine with low toxicity in the treatment of pancreatic
cancer. Br J Pharmacol. 160:998–1007. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu W and McArthur G: Cell cycle regulation
and melanoma. Curr Oncol Rep. 18:342016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan YB: Creatine kinase in cell cycle
regulation and cancer. Amino acids. 48:1775–1784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jirawatnotai S, Aziyu A, Osmundson EC,
Moons DS, Zou X, Kineman RD and Kiyokawa H: Cdk4 is indispensable
for postnatal proliferation of the anterior pituitary. J Biol Chem.
279:51100–51106. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martín A, Odajima J, Hunt SL, Dubus P,
Ortega S, Malumbres M and Barbacid M: Cdk2 is dispensable for cell
cycle inhibition and tumor suppression mediated by p27 (Kip1) and
p21 (Cip1). Cancer Cell. 7:591–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abukhdeir AM and Park BH: P21 and p27:
Roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10:e192008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kiraz Y, Adan A, Yandim M Kartal and Baran
Y: Major apoptotic mechanisms and genes involved in apoptosis.
Tumour Biol. 37:8471–8486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Monian P and Jiang X: Clearing the final
hurdles to mitochondrial apoptosis: Regulation post cytochrome C
release. Exp Oncol. 34:185–191. 2012.PubMed/NCBI
|
|
31
|
Huber HJ, Duessmann H, Wenus J, Kilbride
SM and Prehn JH: Mathematical modelling of the mitochondrial
apoptosis pathway. Biochim Biophys Acta. 1813:608–615. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanai M, Konda Y, Nakajima T, Izumi Y,
Kanda N, Nanakin A, Kubohara Y and Chiba T:
Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity
involved in gastric cancer cell proliferation via MEK-ERK-dependent
pathway. Oncogene. 22:548–554. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu LF, Cheng Y, Qiao MM, Zhang YP and Wu
YL: Activation of STAT3 signaling in human stomach adenocarcinoma
drug-resistant cell line and its relationship with expression of
vascular endothelial growth factor. World J Gastroenterol.
11:875–879. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schauer M, Janssen KP, Rimkus C, Raggi M,
Feith M, Friess H and Theisen J: Microarray-based response
prediction in esophageal adenocarcinoma. Clin Cancer Res.
16:330–337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu LF, Zhu YB, Qiao MM, Zhong J, Tu SP and
Wu YL: Constitutive activation and clinical significance of Stat3
in human gastric cancer tissues and cell lines. Zhonghua Yi Xue Za
Zhi. 84:2064–2069. 2004.(In Chinese). PubMed/NCBI
|
|
36
|
Thoennissen NH, Iwanski GB, Doan NB,
Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, et al:
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT
pathway and potentiates antiproliferative effects of gemcitabine on
pancreatic cancer cells. Cancer Res. 69:5876–5884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng Q, Liu Y, Liu W, Ma F, Zhou Y, Chen
M, Chang J, Wang Y, Yang G and He G: Cucurbitacin B inhibits growth
and induces apoptosis through the JAK2/STAT3 and MAPK pathways in
SH-SY5Y human neuroblastoma cells. Mol Med Rep. 10:89–94.
2014.PubMed/NCBI
|
